{"nctId":"NCT00604708","briefTitle":"Immunogenicity Study of the Japanese Encephalitis Vaccine IC51","startDateStruct":{"date":"2005-09"},"conditions":["Japanese Encephalitis"],"count":867,"armGroups":[{"label":"IC51","type":"EXPERIMENTAL","interventionNames":["Biological: IC51"]},{"label":"JE-VAX","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: JE-VAX"]}],"interventions":[{"name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]},{"name":"JE-VAX","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Written informed consent obtained prior to study entry\n\nExclusion Criteria:\n\n* History of clinical manifestation of any flavivirus infection\n* History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \\>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)\n* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine\n* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy\n* A family history of congenital or hereditary immunodeficiency\n* History of autoimmune disease\n* Any acute infections within 4 weeks prior to enrollment\n* Infection with HIV, Hepatitis B or Hepatitis C\n* Pregnancy, lactation or unreliable contraception in female subjects","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56","description":"SCR: anti-JEV neutralizing antibody titer â‰¥1:10","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Adverse Events","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Immunogenicity at Day 28","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Immunogenicity at Day 56 for North America vs. Europe","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Immunogenicity at Day 56 for Subjects Older vs. Younger Than 50 Years of Age","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"GMT (Geometric Mean Titer) of IC51 Compared to JE-VAX at Day 56","description":"GMT: geometric mean of PRNT50","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"243.6","spread":"1163.1"},{"groupId":"OG001","value":"102","spread":"221"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":428},"commonTop":["Headache","Myalgia","Influenza like Ilness","Fatigue","Nausea"]}}}